Interval debulking surgery for advanced epithelial ovarian cancer: A Cochrane systematic review

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 257-264

  Tangjitgamol, Siriwan ^a   Manusirivithaya, Sumonmal ^a   Laopaiboon, Malinee ^b   Lumbiganon, Pisake ^c  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Advanced epithelial ovarian cancer; Interval debulking surgery; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; CYTOREDUCTIVE SURGERY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVARY CANCER; PARESTHESIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SKIN TINGLING; SYSTEMATIC REVIEW;

FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 57649183685     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.041     Document Type: Review

References (47)

1. In: Parkin D.M., Whelan S.L., Ferlay J., Teppo L., and Thomas D.B. (Eds). Cancer incidence in five continents Volume 8 (2002), IARC Scientific Publication No. 155, Lyon
2. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
3. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. J. Natl. Cancer Inst. Monogr. 42 (1975) 101-104
4. Hoskins W.J., McGuire W.P., Brady M.F., Homsley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-980
5. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 91 (2001) 2329-2334
6. Chan Y.M., Ng T.Y., Ngan H.Y., and Wong L.C. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol. Oncol. 88 (2003) 9-16
7. Giannopoulos T., Butler-Manuel S., Taylor A., Ngeh N., and Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur. J. Gynaecol. Oncol. 27 (2006) 25-28
8. Kuhn W., Rutke S., Spathe K., Schmalfeldt B., Florack G., von Hundelshausen B., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 92 (2001) 2585-2591
9. Lee S.J., Kim B.G., Lee J.W., Park C.S., Lee J.H., and Bae D.S. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J. Obstet. Gynaecol. Res. 32 (2006) 99-106
10. Jacob J.H., Gerhenson D.M., Morris M., Copeland L.J., Burke T.W., and Wharton J.T. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 42 (1991) 146-150
11. Lawton F.G., Redman C.W., Luesley D.M., Chan K.K., and Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet. Gynecol. 73 (1989) 61-65
12. Morice P., Dubernard G., Rey A., Atallah D., Pautier P., Pomel C., et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J. Am. Coll. Surg. 197 (2003) 955-963
13. Surwit E., Childers J., Atlas I., Nour M., Hatch K., Hallum A., et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int. J. Gynecol. Cancer 6 (1996) 356-361
14. Kayikciog L.F., Kose M.F., Boran N., Caliskan E., and Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced ovarian carcinoma. Int. J. Gynecol. Cancer 11 (2001) 466-470
15. Loizzi V., Cormio G., Resta L., Rossi C.A., Di Gilio A.R., Cuccovillo A., et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int. J. Gynecol. Cancer 15 (2005) 217-223
16. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., and Thiel R.P. Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol. Oncol. 72 (1999) 93-99
17. Shibata K., Kikkawa F., Mika M., Suzuki Y., Kajiyama H., Ino K., et al. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors. Int. J. Gynecol. Cancer 13 (2003) 587-592
18. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71 (1998) 431-436
19. Fanfani F., Ferrandina G., Corrado G., Fagotti A., Vito Zakut H., Mancuso S., et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 65 (2003) 316-322
20. Mazzeo F., Berliere M., Kerger J., Squifflet J., Duck L., D'Hondt V., et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol. Oncol. 90 (2003) 163-169
21. Redman C.W., Warwick J., Luesley D.M., Varma R., Lawton F.G., and Blackledge G.R. Intervention debulking surgery in advanced epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 101 (1994) 142-146
22. van der Burg M.E.L., Van Lent M., Buyse M., Kobierska A., Maggioni A., Favalli G., et al. The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC gynecological cancer cooperative group study. New Engl. J. Med. 332 (1995) 629-634
23. Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New Engl. J. Med. 351 (2004) 2489-2497
24. van der Burg M.E.L., Coens C., Van Lent M., Kobierska A., Colombo M., Favalli G., et al. The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; the EORTC GCG 55865 study. Int. J. Gynecol. Cancer 15 Suppl 2 (2005) 79
25. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol. 103 (2006) 1070-1076
26. Bristow R.E., Eisenhauer E.L., Santillan A., and Chi D.S. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol. Oncol. 104 (2007) 480-490
27. Morrison J., Swanton A., Collins S., and Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev. 4 (2007) CD005343
28. Liu E.L., and Mi R.R. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Chin. Med. J. 117 (2004) 1547-1551
29. Elit A.n., and Carey M. The role of interval debulking surgery in advanced ovarian cancer: a meta-analysis. Int. J. Gynecol. Cancer 5 Suppl 1 (1995) 37 (abstract)
30. Palmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17 (1998) 2815-2834
31. Kumar L., Hariprasad R., Kumar S., Bhatla N., Thulkar S., Vijayaraghavan M., et al. Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study - interim results [abstract 5531]. Proc. Am. Soc. Clin. Oncol. 25 Suppl 18 (2007 (meeting part I))
32. Janga D., Kumar L., Kumar S., Shukla N.K., Thulkar S., and Singh R. Neoadjuvant chemotherapy (CT) followed by debulking surgery vs upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma (EOC): a prospective, randomized study [abstract 1957]. Proc. Am. Soc. Clin. Oncol. 22 Suppl 14 (2003 (meeting))
33. Evdokimova N.I., and Grigorova T.M. Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer [abstract]. Vopr. Onkol. 28 (1982) 28-34
34. Park Simon T., Jänicke F., Ortmann O., Hilfrich J., Breitbach G., Höss C., et al. A randomized multicenter phase II study on neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian carcinomas (PRIMOVAR) [abstract 15025]. Proc. Am. Soc. Clin. Oncol. 24 Suppl 18 (2006 (meeting))
35. Dutta T., Sharma H., Kumar L., Dinda A.K., Kumar S., Bhatla N., et al. Neoadjuvant chemotherapy for epithelial ovarian cancer-role of apoptosis. Cancer Chemother. Pharmacol. 56 (2005) 427-435
36. Fuso L., Amant F., Neven P., Berteloot P., and Vergote I. Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 60-67
37. Angioli R., Palaia I., Zullo M.A., Muzii L., Manci N., Calcagno M., et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol. Oncol. 100 (2006) 455-461
38. Solomon J. The role of surgical reexploration following chemotherapy in ovarian cancer. Aust. N. Z. J. Obstet. Gynaecol. 28 (1988) 121-126
39. Recchia F., De Filippis S., Rosselli M., Saggio G., Carta G., and Rea S. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur. J. Gynaecol. Oncol. 22 (2001) 287-291
40. Ikeba K., Okubo M., Takeda S., Kinoshita K., and Maeda H. Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer. Int. J. Clin. Oncol. 9 (2004) 113-119
41. Wenzel L., Huang H.Q., Monk B.J., Rose P.G., and Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 (2005) 5605-5612
42. van der Burg M.E., and Vergote I. Gynecological Cancer Group of the EORTC. The role of interval debulking surgery in ovarian cancer. Curr Oncol Rep 5 (2003) 473-481
43. Kehoe S., Shafi M., Luesley D., Neijt J.P., Cannistra S.A., van der Burg M.E.L., et al. Interval cytoreduction in ovarian cancer. N. Engl. J. Med. 333 (1995) 254-255
44. Kehoe S, Wheeler S. CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. Available at http://www.ctu.mrc.ac.uk/studies/CHORUS.asp (accessed July 11, 2008).
45. Vergote I, Pecorelli S, Stuart G. Intergroup Study (EORTC 55971/NCIC OV13). A randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Available at http://www.cancer.gov/clinicaltrials/EORTC-55971 (accessed July 11, 2008).
46. Onda T., Matsumoto H., Shibata K., Sato T., Fukuda A., Konishi H., et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn. J. Clin. Oncol. 38 (2008) 74-77.
47. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2008;4. Art. No.: CD006014, doi:10.1002/14651858.CD006014.pub2.